Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.
"This article will serve as a landmark reference for navigating short-term labor challenges in radiology," explains one editorial about the suggestions.
The FDA has cleared a focused-ultrasound developer to compare the safety and efficacy of acoustic energy for treating prostate cancer against the more conservative approach of active surveillance.
Editor David Bluemke, MD, PhD, says the journal’s rising impact factor is “representative of the fundamental importance of imaging throughout our hospitals and clinics.”
An imaging OEM is teaming with a multi-omics diagnostics company to offer lung-cancer care teams lab data alongside radiologic findings and clinical histories.
One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality.
Rumors have been swirling for more than a year, but a Siemens Healthineers C-suite executive has declared the company’s ultrasound business alive, well and amply resourced.
Prior to the final proposal’s release, the American College of Radiology reached out to CMS to offer its recommendations on payment rates for five out of the six the new codes.